Bortezomib before and after high-dose therapy in transplant-eligible patients with newly diagnosed multiple myeloma: Long-term overall survival after more than 10 years of follow-up from the phase III HOVON-65/GMMG-HD4 trial
Hemasphere. 2024 Nov 20;8(11):e70052.
doi: 10.1002/hem3.70052.
eCollection 2024 Nov.
1 Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital and Medical Faculty Heidelberg Heidelberg University Heidelberg Germany.
2 Medical Clinic for Hematology Oncology and Tumor Immunology, Charité Berlin Berlin Germany.
3 Department of Hematology VU University Medical Center Amsterdam The Netherlands.
4 HOVON, Rotterdam, The Netherlands and Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands.
5 Department of Hematology VU University Medical Center, Cancer Center Amsterdam Amsterdam The Netherlands.
6 Medical Clinic and Polyclinic II University Hospital Hamburg-Eppendorf Hamburg Germany.
7 Department of Hematology Radboud University Medical Center Nijmegen The Netherlands.
8 Institute of Human Genetics Medical Faculty Heidelberg, University of Heidelberg Heidelberg Germany.
9 Department of Medicine Roswell Park Comprehensive Cancer Center Buffalo New York USA.
10 Laboratorium Tumor Genetica Radboud University Medical Centre Nijmegen The Netherlands.
11 Department of Hematology Erasmus MC Cancer Institute Rotterdam The Netherlands.
12 Department of Internal Medicine University Hospital Maastricht Maastricht The Netherlands.
13 Internal Medicine III, Oncology, Hematology and Rheumatology University Hospital Bonn Bonn Germany.
14 Department of Hematology Haga Hospital The Hague The Netherlands.
15 Department of Hematology University Hospital Essen Essen Germany.
16 Division of Biostatistics German Cancer Research Center (DKFZ) Heidelberg Heidelberg Germany.
17 Department of Hematology and Oncology Asklepios Hospital Hamburg Altona Hamburg Germany.
18 Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn University of Cologne Cologne Germany.
19 National Center for Tumor Diseases (NCT) Heidelberg University Hospital Heidelberg Germany.